Arbutus Biopharma (ABUS) Receivables - Accured (2022 - 2025)
Historic Revenue - Other for Arbutus Biopharma (ABUS) over the last 8 years, with Q2 2017 value amounting to $721000.0.
- Arbutus Biopharma's Revenue - Other rose 16028.88% to $721000.0 in Q2 2017 from the same period last year, while for Jun 2017 it was $1.8 million, marking a year-over-year decrease of 8187.16%. This contributed to the annual value of $10.0 million for FY2017, which is 69381.93% up from last year.
- Latest data reveals that Arbutus Biopharma reported Receivables - Accured of $300000.0 as of Q3 2025, which was down 0.0% from $100000.0 recorded in Q2 2025.
- In the past 5 years, Arbutus Biopharma's Receivables - Accured registered a high of $600000.0 during Q4 2022, and its lowest value of $100000.0 during Q2 2025.
- Moreover, its 4-year median value for Receivables - Accured was $450000.0 (2022), whereas its average is $425000.0.
- Per our database at Business Quant, Arbutus Biopharma's Revenue - Other crashed by 9979.92% in 2013 and then surged by 3910000.0% in 2014.
- Quarter analysis of 5 years shows Arbutus Biopharma's Revenue - Other stood at $5.0 million in 2013, then crashed by 79.69% to $1.0 million in 2014, then surged by 705.67% to $8.2 million in 2015, then plummeted by 97.62% to $196000.0 in 2016, then skyrocketed by 267.86% to $721000.0 in 2017.
- Its Revenue - Other stands at $721000.0 for Q2 2017, versus $217000.0 for Q1 2017 and $196000.0 for Q4 2016.